Literature DB >> 17761847

Effectiveness of novel imidazole-dioxolane heme oxygenase inhibitors in renal proximal tubule epithelial cells.

Robert T Kinobe1, Yanbin Ji, Jason Z Vlahakis, Roberto Motterlini, James F Brien, Walter A Szarek, Kanji Nakatsu.   

Abstract

To enhance our understanding of the physiological roles of heme oxygenase (HO) isozymes, HO-1 (inducible) and HO-2 (constitutive), we developed novel imidazole-based HO inhibitors. Unlike the metalloporphyrins, these imidazole-dioxolane compounds are selective for the in vitro inhibition of HO with minimal effects on other heme-dependent enzymes such as nitric oxide synthase and soluble guanylyl cyclase. In the current study, we tested the hypothesis that these novel HO inhibitors are effective in intact cells by extending their application to cultured, renal proximal tubule epithelial cells (LLC-PK1). HO-1 and HO-2 protein expression was enhanced by pretreatment of cells with hemin, transduction with adenovirus encoding human HO-1, and transfection with cDNA for HO-2, respectively. Total HO activity was measured by determining the formation of carbon monoxide (CO), whereas cell viability and apoptosis were measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and the expression of activated caspase-3. Gliotoxin/tumor necrosis factor-alpha (TNF-alpha) produced cytotoxicity in wild-type LLC-PK1 cells (P < 0.05) but not in HO-1 and HO-2 overexpressing or wild type cells pretreated with hemin (10 microM). The presence of imidazole-dioxolane HO inhibitors (2-25 microM) decreased cell viability (P < 0.05). A CO-releasing molecule reversed, in a dose-dependent manner, the cytotoxic effects and caspase-3 activation induced by the combination of gliotoxin/TNF-alpha and the HO inhibitors, suggesting an important role for CO in protection against renal toxicity. These data demonstrate a protective role of both HO-1 and HO-2 against gliotoxin/TNF-alpha-induced cytotoxicity in LLC-PK1 cells. The novel imidazole-dioxolane compounds can be used as effective inhibitors of HO activity in cell culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761847     DOI: 10.1124/jpet.107.119800

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  In vivo inhibition of renal heme oxygenase with an imidazole-dioxolane inhibitor.

Authors:  Eva Csongradi; Trinity Vera; John M Rimoldi; Rama S V Gadepalli; David E Stec
Journal:  Pharmacol Res       Date:  2010-03-23       Impact factor: 7.658

2.  Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds.

Authors:  Mona N Rahman; Dragic Vukomanovic; Jason Z Vlahakis; Walter A Szarek; Kanji Nakatsu; Zongchao Jia
Journal:  J R Soc Interface       Date:  2012-11-08       Impact factor: 4.118

Review 3.  Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  Transl Res       Date:  2015-06-23       Impact factor: 7.012

4.  Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.

Authors:  Ignazio Barbagallo; Angelo Vanella; Stephen J Peterson; Dong Hyun Kim; Daniele Tibullo; Cesarina Giallongo; Luca Vanella; Nunziatina Parrinello; Giuseppe A Palumbo; Francesco Di Raimondo; Nader G Abraham; David Asprinio
Journal:  J Bone Miner Metab       Date:  2009-11-19       Impact factor: 2.626

5.  Novel insights into the vasoprotective role of heme oxygenase-1.

Authors:  Emanuela Marcantoni; Luigia Di Francesco; Melania Dovizio; Annalisa Bruno; Paola Patrignani
Journal:  Int J Hypertens       Date:  2012-02-22       Impact factor: 2.420

6.  Renal Inhibition of Heme Oxygenase-1 Increases Blood Pressure in Angiotensin II-Dependent Hypertension.

Authors:  Eva Csongradi; Megan V Storm; David E Stec
Journal:  Int J Hypertens       Date:  2011-11-16       Impact factor: 2.420

7.  Role of heme oxygenase-1 in the pathogenesis and tumorigenicity of Kaposi's sarcoma-associated herpesvirus.

Authors:  Lu Dai; Jing Qiao; David Nguyen; Amanda P Struckhoff; Lisa Doyle; Karlie Bonstaff; Luis Del Valle; Chris Parsons; Bryan P Toole; Rolf Renne; Zhiqiang Qin
Journal:  Oncotarget       Date:  2016-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.